This document discusses the treatment of iron deficiency anemia with ferric carboxymaltose (FCM). It begins by defining anemia and iron homeostasis. It then covers the diagnosis of iron deficiency anemia and treatment options. Oral iron is usually first-line but can cause gastrointestinal side effects and issues with compliance. Intravenous FCM is indicated for patients who fail or do not tolerate oral iron, have malabsorption issues, or require a rapid response. The document provides guidelines on diluting and administering FCM intravenously to effectively treat iron deficiency anemia while minimizing risks.